PTEN and metastatic neoplasm: p53 inactivation or abnormal expression has been demonstrated to be associated with adverse patient clinical outcomes and metastatic disease while high expression of ERG and PTEN-loss have been demonstrated to be clinically relevant to shorter patient survival, higher Gleason scores and unfavorable pathological and clinical outcomes [32].